Clinical trial failure
DurAVR® depends on PARADIGM Trial success to support regulatory approval and commercialization.
- Scope
- Lead product development
- Materiality
- high
Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a development-stage structural heart company focused on designing and commercializing the DurAVR® transcatheter heart valve system for patients with aortic stenosis. The company’s core technology is its proprietary ADAPT® anti-calcification tissue platform, which it is using to build a single-piece, biomimetic valve intended to improve durability and performance. In addition to its lead clinical program, Anteris has historically generated limited revenue from regenerative tissue products such as CardioCel™ and VascuCel™, mainly through supply arrangements with 4C Medical Technologies and LeMaitre Vascular. The business is still pre-commercial for its lead product and is spending heavily on clinical trials, manufacturing scale-up, and regulatory work to support the PARADIGM Trial and eventual FDA approval.
−4 821,4 %
70,3 %
−4 921,3 %
−29,2 %
0.73
0.73
| % | |
|---|---|
| Structural heart / transcatheter valve system | 0% Lead development program for the DurAVR® THV system, a single-piece transcatheter aortic valve for aortic stenosis. |
| Regenerative tissue products | 100% Commercial sales of CardioCel™ and VascuCel™ patches and related tissue products sold under supply arrangements. |
| Proprietary tissue platform | 0% ADAPT® anti-calcification tissue technology used as the core biomaterial platform for the company’s valve and tissue products. |
| Clinical and regulatory development | 0% Clinical trial execution, site qualification, IDE/PMA work, and manufacturing readiness for the PARADIGM Trial. |
Anteris currently sells regenerative tissue products primarily to medical-device companies and distributors rather than...
- Medical-device OEM partnerprimary
4C Medical Technologies purchases regenerative tissue products under a supply and license arrangement to support its own device programs.
- Distributor / channel partnerprimary
LeMaitre Vascular historically bought and distributed CardioCel™ and VascuCel™ patches, providing commercial revenue from tissue products.
- Clinical trial sitesprimary
Hospitals and centers in the U.S., Europe, and Canada qualify for and participate in the PARADIGM Trial, enabling product validation and regulatory progress.
- Future hospital and physician userssecondary
Structural heart programs and interventional cardiologists are the eventual buyers/users of DurAVR® once the product is approved and commercialized.
Anteris is headquartered in the United States and is building its lead clinical program around trial sites across the U...
- •United States is the corporate base and a key market for the PARADIGM Trial
- •Europe is part of the planned trial footprint and future commercialization pathway
- •Canada is included among qualified trial regions for PARADIGM
- •Australia is important for R&D activity and tax incentive support
- •Revenue is currently concentrated in limited supply relationships rather than broad country sales
- •Geographic execution risk is driven by multi-country clinical and regulatory coordination
Anteris’ strategy is centered on completing the PARADIGM Trial and advancing the DurAVR® THV system through FDA review...
01
Complete PARADIGM Trial executionshort-term
Clinical success is the main gate to FDA PMA and future commercialization of DurAVR®.
02
Scale manufacturing readinessshort-term
The company must produce trial inventory and later commercial supply reliably to support regulatory and market adoption.
03
Secure additional capitalshort-term
Current cash is not expected to fund operations for 12 months, so financing is required to continue development.
04
Transition from development to commercializationmedium-term
Long-term value depends on obtaining approval and converting clinical progress into product sales.
The company faces substantial execution risk because its lead product is still in clinical development and depends on...
Regulatory approval risk
The FDA could delay, deny, or revoke IDE/PMA status, preventing market entry.
- Scope
- DurAVR® THV system
- Materiality
- high
Financing and dilution risk
The company expects to need additional capital and may rely on equity issuance or debt.
- Scope
- Corporate liquidity
- Materiality
- high
Manufacturing scale-up risk
Trial and future commercial supply depend on successful process validation and inventory build.
- Scope
- Operations and supply chain
- Materiality
- medium
Commercial adoption risk
Even with approval, physicians and hospitals may adopt the product slowly if evidence or economics are not compelling.
- Scope
- Future revenue ramp
- Materiality
- medium
Revenue recognition on supply contracts
Quarterly revenue volatility
Australian R&D tax incentive income
Non-operating income variability
Lease accounting
Balance sheet obligations and liquidity analysis
VIE consolidation judgments
Scope of consolidation and reported assets/liabilities
Edwards Lifesciences Corp
EW · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Edwards Lifesciences designs and sells structural heart therapies used to treat advanced cardiovascular disease, with a portfolio centered on transcatheter and surgical valve technologies.
ARTIVION, INC.
AORT · Surgical & Medical Instruments & Apparatus
AtriCure, Inc.
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Humacyte, Inc.
HUMA · Biological Products, (No Diagnostic Substances)
TENAX THERAPEUTICS, INC.
TENX · Pharmaceutical Preparations
: 11/08/2026